Wednesday, October 8, 2025

Latest

Willow Biosciences Looks To Launch Biosynthesized THC In Canadian Market

Willow Biosciences (TSX: WLLW) this morning had a major announcement, with the company announcing that it has advanced its work on biosynthesizing tetrahydrocannabinol, or THC. The company has successfully advanced the proprietary yeast strain required for biosynthetic production of THC, and plans to launch the product into the Canadian market.

The company has successfully developed the yeast strain and process for the production of THC to enable the company to provide guidance of a pilot scale run occurring later this year. For this, the company has reportedly already identified a development partner for isolation, purification, and scale up for its pilot production run, while the firm is in talks with several manufacturing companies to serve the adult-use cannabis market.

As with its cannabigerol, or CBG, product, the company believes that there is significant demand from consumer product manufacturers for the production of a consistent, high-purity, odorless, flavourless THC ingredient for the cannabis 2.0 market. Specifically, Willow will look to provide its THC product to producers of vapes, edibles, beverages, concentrates and topicals within the cannabis sector.

In terms of markets, the company has indicated that it will first launch its THC product the Canadian market where THC is legalized, while following the developments in the US and being ready to act for when a legalization event occurs.

“From conversations with prospective customers in Canada, we believe that there is significant demand for consistent, high-purity THC. The flavourless, odorless attributes of our finished product make it suitable as a core ingredient for the cannabis 2.0 market in Canada. There is also strong demand for a more sustainable and environmentally friendly way to produce THC. Our manufacturing process is 50 to 500 times more efficient than indoor cultivation and is the next evolution of sustainable cannabinoid manufacturing.”

Trevor Peters, CEO of Willow Biosciences

A specific time frame for the initial pilot production of THC via biosynthesis was not provided.

Willow Biosciences last traded at $1.23 on the TSX.


FULL DISCLOSURE: Willow Biosciences Inc is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Willow Biosciences Inc on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Willow Biosciences Increases Bought Deal Financing To $25.0 Million

Late last night, Willow Biosciences (TSX: WLLW) announced the upsizing of its bought deal financing...

Friday, February 12, 2021, 07:25:43 AM

THC Production From Yeast – The Daily Dive feat Trevor Peters of Willow Biosciences

Today on the Daily Dive, we sit down with Trevor Peters, CEO of Willow Biosciences...

Wednesday, February 3, 2021, 01:30:00 PM

Willow Biosciences To Raise $20.0 Million In Bought Deal Financing

Willow Biosciences (TSX: WLLW) this evening announced that it will be conducting a bought deal...

Thursday, February 11, 2021, 06:10:22 PM

Willow Biosciences Announces First Commercial Production Of CBG To Occur In Q1 2021

Willow Biosciences (TSX: WLLW) announced major news this morning in that it has advanced its...

Wednesday, December 16, 2020, 08:03:32 AM

Willow Biosciences: First Commercial Fermentation Of CBG Completed – The Daily Dive

Today on the Daily Dive, we sit down with that of Trevor Peters, CEO of...

Wednesday, March 31, 2021, 01:30:00 PM